№ lp_1_14749
File format: docx Character count: 19282 File size: 89 KB
Policy source detailing clinical commissioning and funding arrangements for TAF-based ART regimens in England.
Year: 2021
Region: England
Subject: HIV-1 treatment
Document type: Clinical commissioning policy
Organization: NHS England
Target audience: Adults and adolescents living with HIV-1
Approved date: 2021
Drug reviewed: Tenofovir alafenamide (TAF)
Treatment context: Antiretroviral therapy (ART)
Purpose: Funding and clinical guidance for TAF use
Evidence reviewed: Comparative safety and efficacy versus TDF
Population: Patients with contraindications to TDF or with complications during treatment
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Clinical Commissioning Policy Tenofovir alafenamide for treatment of HIV 1 in adults and adolescents
Year: 2025
Region / City: England
Theme: HIV Treatment, Antiretroviral Therapy
Document Type: Policy Statement
Organization / Institution: NHS England
Author: NHS England
Target Audience: Healthcare professionals, policy makers
Effective Period: Ongoing from May 2025
Approval Date: May 2025
Date of Last Update: August 2025
Tenofovir alafenamide, TABLET 25 MG, VEMLIDY®, GILEAD SCIENCES
Year: 2017
Region / city: Australia
Subject: Chronic Hepatitis B, Antiviral Therapy
Document Type: Submission for PBS listing
Agency / institution: PBAC (Pharmaceutical Benefits Advisory Committee)
Author: GILEAD SCIENCES
Target audience: Healthcare professionals, policymakers
Period of validity: Not specified
Approval date: 22 February 2017
Amendment date: Not specified
Modified protocol for lentiviral vectors pseudotyped with EnvA, EnvB, Ebola, MMLV or HIV-1 glycoproteins
Year: N/A
Region / city: N/A
Topic: Lentiviral vector production
Document type: Protocol
Organization / institution: N/A
Author: N/A
Target audience: Researchers in molecular biology
Validity period: N/A
Approval date: N/A
Date of changes: N/A
Context description: Protocol for the production and purification of lentiviral vectors, including detailed steps for DNA transfection, virus collection, and purification using Optiprep.
PrEP ELIGIBILITY SCORE SHEET COHORT-DERIVED HIV-1 RISK SCORE (CDHRS) TOOL FOR MSM: circle score and calculate total risk score
Year: Not specified
Region / City: Not specified
Topic: HIV prevention, PrEP eligibility
Document Type: Risk assessment tool
Organization / Institution: Ministry of Health (MoH)
Author: Not specified
Target Audience: Men who have sex with men (MSM)
Validity Period: Not specified
Approval Date: Not specified
Modification Date: Not specified
Clinical Commissioning Policy Tenofovir alafenamide for treatment of HIV 1 in adults and adolescents
Year: 2025
Region / City: England
Theme: HIV Treatment, Antiretroviral Therapy
Document Type: Policy Statement
Organization / Institution: NHS England
Author: NHS England
Target Audience: Healthcare professionals, policy makers
Effective Period: Ongoing from May 2025
Approval Date: May 2025
Date of Last Update: August 2025
Tenofovir alafenamide, TABLET 25 MG, VEMLIDY®, GILEAD SCIENCES
Year: 2017
Region / city: Australia
Subject: Chronic Hepatitis B, Antiviral Therapy
Document Type: Submission for PBS listing
Agency / institution: PBAC (Pharmaceutical Benefits Advisory Committee)
Author: GILEAD SCIENCES
Target audience: Healthcare professionals, policymakers
Period of validity: Not specified
Approval date: 22 February 2017
Amendment date: Not specified
Supplementary file: LC-MS/MS analysis of tenofovir in urine and DBS samples with point-of-care TFV results
Year: 2026
Region: Not specified
Document type: Supplementary material / Research data
Methods: LC-MS/MS, IP–HILIC–MS/MS
Analytes: Tenofovir (TFV), Tenofovir-diphosphate (TFV-DP)
Sample types: Urine, Dried Blood Spots (DBS)
Target population: Participants on antiretroviral therapy (ART)
Measured variables: Urine TFV concentration, DBS TFV-DP concentration, POC TFV results, self-reported adherence, viral load, drug resistance
Instrument: Agilent HPLC coupled to AB Sciex 5500 triple quadrupole mass spectrometer
Software: Analyst v1.6.2
Detection method: Negative-ion multiple reaction monitoring (MRM)
Tables included: S1, S2, S3, S4
Information for patients switching from Atripla® to generic tenofovir, emtricitabine and efavirenz
Year: 2018
Region / city: United Kingdom, Ireland
Subject: Medicine information
Document type: Patient information leaflet
Organization: HIV Pharmacy Association (HIVPA)
Author: HIV Pharmacy Association (HIVPA)
Target audience: Patients switching from Atripla to generic tenofovir, emtricitabine, and efavirenz
Effective period: From February 2018
Approval date: February 2018
Date of changes: Not mentioned
Contact: Telephone number: [Provided in document]
Topics: alafenamide HIV-1 Tenofovir